This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
by Zacks Equity Research
Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.
Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why
by Zacks Equity Research
Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
by Zacks Equity Research
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
by Zacks Equity Research
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.
Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
by Zacks Equity Research
This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 101.09%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 101.1% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
by Zacks Equity Research
Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Arcutis Biotherapeutics, Inc. (ARQT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adverum Biotechnologies (ADVM) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 54.8% in Arcutis Biotherapeutics, Inc. (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 58.9% upside potential for Arcutis Biotherapeutics, Inc. (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Athira Pharma, Inc. (ATHA) have performed compared to their sector so far this year.
Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on Avalo Therapeutics' (AVTX) lead pipeline drug when it reports fourth-quarter earnings results.
Ginkgo (DNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Ginkgo's (DNA) fourth-quarter earnings call, investor focus is likely to be on the sales performance of its two business units, Biosecurity and Cell Engineering.
Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.
Has Apellis Pharmaceuticals (APLS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Apellis Pharmaceuticals, Inc. (APLS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Eli Lilly (LLY) Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales
by Zacks Equity Research
Eli Lilly (LLY) beats fourth-quarter estimates for earnings as well as sales. The company issues an upbeat guidance for 2024.
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
by Zacks Equity Research
Assertio (ASRT) appears weighed down by the recent leadership transition. The company is also facing challenges with sales of its product franchisee of late.
Are Medical Stocks Lagging AlloVir (ALVR) This Year?
by Zacks Equity Research
Here is how AlloVir, Inc. (ALVR) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Arcutis Biotherapeutics, Inc. (ARQT) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Arcutis Biotherapeutics, Inc. (ARQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for January 11th (Revised)
by Zacks Equity Research
ADMA and ARQT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 11, 2024.